Rifampin breakpoint for acinetobacter baumannii based on pharmacokineticpharmacodynamic models with Monte Carlo simulation;evaluación de un punto de corte farmacocinético-farmacodinámico para rifampicina en acinetobacter baumannii mediante simulación de Monte-Carlo

Revista Espanola de Quimioterapia

Volumn 25, Issue 2, 2012, Pages 134-138

  Lepe, José Antonio ^a,b   García Cabrera, Emilio ^a,b   Gil Navarro, María Victoria ^a   Aznar, Javier ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Department of Internal Medicine   (Spain)

Author keywords

Acinetobacter; Monte carlo; PK PD; Rifampin

Indexed keywords

RIFAMPICIN;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIUM ISOLATE; CALCULATION; DOSE RESPONSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PROBABILITY; REFERENCE VALUE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FRANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PROBABILITY; REFERENCE VALUES; RIFAMPIN;

EID: 84863703608     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Olaechea PM, Insausti J, Blanco A, Luque P. [Epidemiology and impact of nosocomial infections.]. Med Intensiva 2010; 34: 256-267.
2. Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009; 53: 1295-1296.
3. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 1946-1952.
4. Pachón-Ibáñez ME, Docobo-Pérez F, Jiménez-Mejias ME, Ibáñez-Martínez J, García-Curiel A, Pichardo C et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem- resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 1165-1172.
5. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother 51:3781-3788.
6. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003. 47:2118-2124.
7. Soussy CJ. Les Recommandations du Comité de l'Antibiogramme (CA-SFM) http://www.sfm.asso.fr/publi/general.php?pa=1/casfm.pdf. In: 2010.
8. Houin G, Beucler A, Richelet S, Brioude R, Lafaix C, Tillement JP. Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculosis patients after different rates of infusion. Ther Drug Monit 1983; 5: 67-72.
9. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 2004; 48:3670-3676.
10. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic- pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 2008; 61: 621-628.
11. Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 2003; 52: 893-898.
12. Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006; 58:697-700.
13. Mitchison DA. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis. 1998;2:612-615.
14. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29: 719-724.